Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Leflunomide+Vemurafenib in V600 Mutant Met. Melanoma

This study has suspended participant recruitment.
Sponsor:
Information provided by (Responsible Party):
Keith Flaherty, Massachusetts General Hospital
ClinicalTrials.gov Identifier:
NCT01611675
First received: May 19, 2012
Last updated: September 13, 2016
Last verified: September 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has suspended participant recruitment.
  Estimated Study Completion Date: July 2017
  Estimated Primary Completion Date: July 2017 (Final data collection date for primary outcome measure)